SINGLE-ROUTE CNS PROPHYLAXIS FOR AGGRESSIVE NON-HODGKIN LYMPHOMAS: REAL-WORLD OUTCOMES FROM 21 US ACADEMIC INSTITUTIONS

Autor: Orellana-Noia, VM, Reed, DR, McCook, AA, Sen, JM, Barlow, CM, Malecek, M-K, Watkins, M, Kahl, BS, Spinner, MA, Advani, R, Voorhees, TJ, Snow, A, Grover, NS, Ayers, A, Romancik, JT, Liu, Y, Huntington, SF, Chavez, JC, Saeed, H, Lazaryan, A, Raghunathan, V, Spurgeon, SE, Ollila, TA, Del Prete, C, Olszewski, AJ, Ayers, EC, Landsburg, DJ, Echalier, B, Lee, J, Kamdar, M, Caimi, PF, Fu, T, Liu, J, David, KA, Alharthy, H, Law, J, Karmali, R, Shah, H, Stephens, DM, Major, A, Rojek, AE, Smith, SM, Yellala, A, Kallam, A, Nakhoda, S, Khan, N, Sohail, MA, Hill, BT, Barrett-Campbell, O, Lansigan, F, Switchenko, J, Cohen, JB, Portell, CA
Zdroj: Blood; 20210101, Issue: Preprints
Abstrakt: Prophylaxis is commonly used to prevent central nervous system (CNS) relapse in diffuse large B cell lymphoma, with no clear standard of care. We retrospectively evaluated 1162 adult patients across 21 US academic centers with DLBCL or similar histologies who received single-route CNS prophylaxis as part of frontline therapy between 2013-2019.
Databáze: Supplemental Index